New Article information at Drug Development Technology New and updated information from Article listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New Article information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Rubraca (rucaparib) for the Treatment of Advanced Ovarian Cancer http://www.drugdevelopment-technology.com/projects/rubraca-rucaparib-for-the-treatment-of-advanced-ovarian-cancer/ http://www.drugdevelopment-technology.com/projects/rubraca-rucaparib-for-the-treatment-of-advanced-ovarian-cancer/ Poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor Rubraca™ (rucaparib) is indicated for the treatment of BRCA mutation-linked advanced ovarian cancer. Thu, 19 Jan 2017 00:00:00 GMT 2016: The year's biggest Drug Development Technology stories http://www.drugdevelopment-technology.com/features/feature2016-the-years-biggest-drug-development-technology-stories-5706284/ http://www.drugdevelopment-technology.com/features/feature2016-the-years-biggest-drug-development-technology-stories-5706284/ NIAID began a new HIV vaccine study in South Africa and Eli Lilly’s Phase III trial of Alzheimer disease drug failed. Drugdevelopment-technology wraps-up the key headlines from 2016. Tue, 03 Jan 2017 00:00:00 GMT Soliqua 100/33 for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/soliqua-10033-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/soliqua-10033-for-the-treatment-of-type-2-diabetes/ Developed by Sanofi, Soliqua 100/33 (insulin glargine & Lixisenatide injection) is indicated for the treatment of Type 2 diabetes. Mon, 19 Dec 2016 00:00:00 GMT November’s top stories: Wellcome’s clinical trial network, Eli Lilly’s Alzheimer disease drug trial http://www.drugdevelopment-technology.com/features/featurenovembers-top-stories-wellcomes-clinical-trial-network-eli-lillys-alzheimer-disease-drug-trial-5683416/ http://www.drugdevelopment-technology.com/features/featurenovembers-top-stories-wellcomes-clinical-trial-network-eli-lillys-alzheimer-disease-drug-trial-5683416/ UK’s Wellcome recommended a clinical trial network for efficient drug development, and Eli Lilly’s Alzheimer disease drug trial failed to meet endpoints. Drugdevelopment-technology.com wraps up the key headlines from November. Tue, 06 Dec 2016 00:00:00 GMT Xultophy 100/3.6 for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/xultophy-10036-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/xultophy-10036-for-the-treatment-of-type-2-diabetes/ Developed by Novo Nordisk, Xultophy 100/3.6 is indicated for the treatment of type 2 diabetes. Thu, 01 Dec 2016 00:00:00 GMT Stelara (Ustekinumab) for the Treatment of Moderate to Severe Crohn’s Disease http://www.drugdevelopment-technology.com/projects/stelara-ustekinumab-for-the-treatment-of-moderate-to-severe-crohns-disease/ http://www.drugdevelopment-technology.com/projects/stelara-ustekinumab-for-the-treatment-of-moderate-to-severe-crohns-disease/ Developed by Janssen Biotech, Stelara (Ustekinumab) is indicated for the treatment of moderate to severely active Crohn's disease. Tue, 29 Nov 2016 00:00:00 GMT Vemlidy (Tenofovir Alafenamide) for Treatment of Chronic Hepatitis B Virus Infection http://www.drugdevelopment-technology.com/projects/vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection/ http://www.drugdevelopment-technology.com/projects/vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection/ Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients. Thu, 24 Nov 2016 00:00:00 GMT Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection http://www.drugdevelopment-technology.com/projects/zinplava-bezlotoxumab-for-the-treatment-of-clostridium-difficile-infection/ http://www.drugdevelopment-technology.com/projects/zinplava-bezlotoxumab-for-the-treatment-of-clostridium-difficile-infection/ Zinplava (bezlotoxumab) is an injectable solution developed by Merck indicated for the treatment of clostridium difficile infection (CDI) in adult patients who are already receiving anti-bacterial drug treatment. Tue, 22 Nov 2016 00:00:00 GMT Invokamet XR for the Treatment of Type 2 Diabetes in Adults http://www.drugdevelopment-technology.com/projects/invokamet-xr-for-the-treatment-of-type-2-diabetes-in-adults/ http://www.drugdevelopment-technology.com/projects/invokamet-xr-for-the-treatment-of-type-2-diabetes-in-adults/ Developed by Janssen Pharmaceuticals, Invokamet XR (Canagliflozin / Metformin Hydrochloride Extended Release) is indicated for the treatment of Type 2 diabetes in adults. Thu, 17 Nov 2016 00:00:00 GMT October’s top stories: Eurocine Vaccines initiated influenza vaccine study, IVF usage led to conceiving male child http://www.drugdevelopment-technology.com/features/featureoctobers-top-stories-eurocine-vaccines-influenza-vaccine-study-initiation-ivf-usage-leading-to-conceiving-male-child-5655728/ http://www.drugdevelopment-technology.com/features/featureoctobers-top-stories-eurocine-vaccines-influenza-vaccine-study-initiation-ivf-usage-leading-to-conceiving-male-child-5655728/ Eurocine Vaccines initiated a Phase I/II influenza vaccine study and a new study suggested in-vitro fertilisation increases the chances of conceiving a male child. Drugdevelopment-technology.com wraps up the key headlines from October 2016. Mon, 07 Nov 2016 00:00:00 GMT Lartruvo (olaratumab) for the Treatment of Soft Tissue Sarcoma http://www.drugdevelopment-technology.com/projects/lartruvo-olaratumab-for-the-treatment-of-soft-tissue-sarcoma/ http://www.drugdevelopment-technology.com/projects/lartruvo-olaratumab-for-the-treatment-of-soft-tissue-sarcoma/ Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma in adult patients. Thu, 27 Oct 2016 23:00:00 GMT Exondys 51 (eteplirsen) for the Treatment of Duchenne Muscular Dystrophy (DMD) http://www.drugdevelopment-technology.com/projects/exondys-51-eteplirsen-for-the-treatment-of-duchenne-muscular-dystrophy-dmd/ http://www.drugdevelopment-technology.com/projects/exondys-51-eteplirsen-for-the-treatment-of-duchenne-muscular-dystrophy-dmd/ Exondys 51 (eteplirsen) is an injectable solution developed by Sarepta Therapeutics. Thu, 20 Oct 2016 23:00:00 GMT Carnexiv (carbamazepine) for the Treatment of Partial, Generalised Tonic-clonic Seizures in Adults http://www.drugdevelopment-technology.com/projects/carnexiv-carbamazepine-for-the-treatment-of-certain-seizure-types-in-adults/ http://www.drugdevelopment-technology.com/projects/carnexiv-carbamazepine-for-the-treatment-of-certain-seizure-types-in-adults/ Carnexiv (carbamazepine) is an injectable formulation developed by Lundbeck for partial, generalised tonic-clonic seizures in adult patients who are unable to temporarily take oral medication. Thu, 13 Oct 2016 23:00:00 GMT Dupixent (dupilumab) for the Treatment of Atopic Dermatitis http://www.drugdevelopment-technology.com/projects/dupixent-dupilumab-for-the-treatment-of-atopic-dermatitis/ http://www.drugdevelopment-technology.com/projects/dupixent-dupilumab-for-the-treatment-of-atopic-dermatitis/ Dupixent (dupilumab) is an investigational drug being developed by Sanofi and Regeneron as a treatment for moderate to severe atopic dermatitis in adult patients. Wed, 12 Oct 2016 23:00:00 GMT September's top stories: Oncternal begins TK216 trial, Medical cannabis trials begin in Canada http://www.drugdevelopment-technology.com/features/featureseptembers-top-stories-oncternal-begins-dosing-in-phase-i-trial-of-tk216-phase-ii-trial-of-medical-cannabis-in-canada-begin-5022063/ http://www.drugdevelopment-technology.com/features/featureseptembers-top-stories-oncternal-begins-dosing-in-phase-i-trial-of-tk216-phase-ii-trial-of-medical-cannabis-in-canada-begin-5022063/ Oncternal Therapeutics began dosing patients in its Phase I clinical trial of TK216 to treat Ewing sarcoma and Tilray and University of British Columbia began patient enrolment in Canada’s first Phase II clinical trial of medical cannabis to treat po… Thu, 06 Oct 2016 23:00:00 GMT Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis http://www.drugdevelopment-technology.com/projects/ocrevus-ocrelizumab-for-the-treatment-of-multiple-sclerosis/ http://www.drugdevelopment-technology.com/projects/ocrevus-ocrelizumab-for-the-treatment-of-multiple-sclerosis/ Ocrevus (ocrelizumab), developed by Genentech, a member of Roche Group, is indicated for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis. Thu, 06 Oct 2016 23:00:00 GMT Ibrance (palbociclib) for the Treatment of Metastatic Breast Cancer http://www.drugdevelopment-technology.com/projects/ibrance-palbociclib-for-the-treatment-of-metastatic-breast-cancer/ http://www.drugdevelopment-technology.com/projects/ibrance-palbociclib-for-the-treatment-of-metastatic-breast-cancer/ Ibrance (palbociclib) is an oral formulation developed by Pfizer for the treatment of metastatic breast cancer in women with disease progression post endocrine therapy. Thu, 29 Sep 2016 23:00:00 GMT Afluria Quadrivalent for Prevention of Infection from Influenza Virus http://www.drugdevelopment-technology.com/projects/afluria-quadrivalent-for-prevention-of-infection-from-influenza-virus/ http://www.drugdevelopment-technology.com/projects/afluria-quadrivalent-for-prevention-of-infection-from-influenza-virus/ Afluria Quadrivalent is an inactivated influenza vaccine developed by Seqirus, which is developed to provide active immunisation against the disease. Tue, 13 Sep 2016 23:00:00 GMT GLS-5700 DNA Vaccine for Prevention of Infection from Zika Virus http://www.drugdevelopment-technology.com/projects/gls-5700-dna-vaccine-for-prevention-of-infection-from-zika-virus/ http://www.drugdevelopment-technology.com/projects/gls-5700-dna-vaccine-for-prevention-of-infection-from-zika-virus/ GLS-5700 is a synthetic vaccine being developed by Inovio Pharmaceuticals and GeneOne Life Sciences to prevent and treat infections caused by the Zika virus. Thu, 08 Sep 2016 23:00:00 GMT August's top stories: Gradalis' Phase I breast cancer trial, Biothera and Merck conducted combination cancer immunotherapy trials http://www.drugdevelopment-technology.com/features/featureaugusts-top-stories-gradalis-phase-i-breast-cancer-trial-biothera-and-merck-to-conduct-combination-cancer-immunotherapy-trials-4996151/ http://www.drugdevelopment-technology.com/features/featureaugusts-top-stories-gradalis-phase-i-breast-cancer-trial-biothera-and-merck-to-conduct-combination-cancer-immunotherapy-trials-4996151/ Gradalis dosed the first patient in its pilot Phase I trial of a combination of Vigil Engineered Autologous Tumour Cells (EATCs) and durvalumab to treat advanced breast cancer, and Biothera collaborated with Merck to expand the ongoing clinical progr… Thu, 08 Sep 2016 23:00:00 GMT